Current Report Filing (8-k)
July 09 2018 - 5:46PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): July 9, 2018
CELGENE
CORPORATION
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Delaware
|
|
001-34912
|
|
22-2711928
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
86 Morris Avenue, Summit,
New Jersey
|
|
07901
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (908) 673-9000
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
On July 9, 2018, Celgene Corporation announced results from
a phase III, randomized, double-blind, multi-center clinical study (BELIEVE). Luspatercept achieved a highly statistically significant
improvement in the primary endpoint of erythroid response, which was defined as at least a 33 percent reduction from baseline
in red blood cell (RBC) transfusion burden with a reduction of at least 2 units during the protocol-defined period of 12 consecutive
weeks, from week 13 to week 24, compared to placebo.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
Exhibit 99.1 – Press Release dated July 9, 2018
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CELGENE CORPORATION
|
|
|
|
|
Date: July 9, 2018
|
|
|
|
By:
|
|
/s/ Peter N. Kellogg
|
|
|
|
|
|
|
Peter N. Kellogg
|
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer
(principal financial and accounting officer)
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Oct 2023 to Oct 2024